Chondrocyte culture with high tissue regeneration ability
A chondrocyte culture produced by culturing cells in a thermoreversible polymer enhances gene expression and stem cell content, addressing the limitations of current osteoarthritis treatments by effectively regenerating and maintaining cartilage tissue.
Patent Information
- Application Number
- JP2021513690
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-08
- Filing Date
- 2020-04-08
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2040-04-08
AI Technical Summary
Current treatments for osteoarthritis, such as autologous chondrocyte implantation, fail to effectively restore and maintain the degenerative state of cartilage tissue, leading to chondrocyte apoptosis and fibrocartilage formation, thus requiring a method to normalize and regenerate cartilage tissue.
A method for producing a chondrocyte culture with high tissue regeneration ability by culturing a cell population separated from cartilage tissue in a thermoreversible polymer, enhancing expression of genes like SOX9, COL2A1, miR140, and miR21, and maintaining stem cells to promote hyaluronic acid secretion.
The chondrocyte culture exhibits high engraftment properties, normalizes the degenerative state of cartilage, and maintains cartilage tissue over a long period by promoting ECM synthesis and stem cell differentiation, effectively treating osteoarthritis.
Smart Images

Figure 0007578958000010 
Figure 0007578958000011 
Figure 0007578958000012
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for producing a chondrocyte culture, a chondrocyte culture produced by said method, and a method of treatment using the chondrocyte culture. [Background technology]
[0002] Osteoarthritis is characterized by progressive cartilage damage in joint tissue and is caused by a variety of factors, including aging, joint injury, and obesity, leading to loss of joint function and stiffening, especially in the elderly.
[0003] Articular cartilage tissue consists of a thin hyaline cartilage that exists on the articular surface of the bone epiphysis. Hyaline cartilage has a tissue structure in which the intercellular spaces of chondrocytes are filled with cartilage extracellular matrix (ECM) that forms a higher-order structure through interactions with hyaluronic acid-aggrecan network and type II collagen fibers. The degradation of this ECM is closely related to the damage process of cartilage tissue in OA.
[0004] When cartilage tissue is damaged, type II collagen fibers in the ECM are destroyed, which causes the release of hyaluronan and aggrecan. The released hyaluronan and aggrecan induce apoptosis of chondrocytes and the production of the inflammatory cytokine interleukin-1, which promotes the production and secretion of ECM degrading enzymes such as MMPs, ADAMTS, and HYBIDs, further accelerating the degradation of the ECM in the cartilage tissue.
[0005] In this way, the elasticity of cartilage tissue with degraded ECM is significantly reduced and it becomes brittle, resulting in a vicious cycle in which it is easily damaged even by light loads. Furthermore, unlike normal tissues, articular tissue does not have a blood supply and exchanges materials with the inside and outside of cartilage tissue by diffusion, and there is no inflow of cells. Therefore, once the homeostasis of the tissue is destroyed, as in osteoarthritis, the denatured state is maintained, making it difficult to repair (Non-Patent Documents 1 and 2).
[0006] As a treatment for such osteoarthritis, autologous chondrocyte implantation (ACI) using chondrocytes derived from healthy cartilage tissue harvested from the non-weight-bearing part of the articular cartilage and matrix-induced autologous chondrocyte implantation (MACI) have been performed. Such implantation is effective if healthy cartilage tissue is present around the implantation site, such as in traumatic knee cartilage damage, but even if it is performed in a degenerative site where the homeostasis of the cartilage tissue is destroyed, such as in osteoarthritis, although temporary improvement is observed, the chondrocytes in the implant soon die due to apoptosis or fibrocartilage is formed, and sufficient therapeutic effect is not obtained (Non-Patent Document 3). Thus, in the treatment of osteoarthritis, there is a demand for a treatment that can normalize the degenerated state of cartilage tissue and maintain repair over the long term. [Prior art documents] [Non-patent literature]
[0007] [Non-Patent Document 1] Chen et al.,Bone Res. 2017 Jan 17;5:16044. doi: 10.1038 / boneres.2016.44. eCollection 2017. [Non-Patent Document 2] Zhang et al., Bone Research volume4, Article number: 15040,2016 [Non-Patent Document 3] Niemeyera.et al. The Knee, Volume 23, Issue 3, June 2016, Pages 426-435 Summary of the Invention [Problem to be solved by the invention]
[0008] The present invention provides a method for producing a chondrocyte culture having high tissue regeneration ability, a chondrocyte culture produced by said method, and a therapeutic method using the chondrocyte culture. [Means for solving the problem]
[0009] That is, the present invention relates to the following: [1] A method for producing a chondrocyte culture having high tissue regeneration ability, the method comprising the step of culturing a cell population isolated from cartilage tissue in a thermoreversible polymer. [2] The method according to [1], wherein the tissue regeneration ability is the ability of the chondrocyte culture to express one or more genes selected from SOX9, COL2A1, miR140 and miR21, the ability to retain miRNA, the stem cell content, or the ability to secrete hyaluronic acid. [3] The method according to [2], wherein the miRNA is miR140. [4] The method according to [2] or [3], wherein the stem cells are pluripotent stem cells or somatic stem cells with high differentiation potential. [5] The method according to any one of [2] to [4], wherein the stem cell content is the content of 1-2 fucose or α2-6 sialic acid in the chondrocyte culture. [6] The method according to [1] to [5], wherein the cartilage tissue is derived from a subject aged 50 years or older with osteoarthritis. [7] The method according to any one of [1] to [6], wherein the thermoreversible polymer is a thermoreversible polymer to which no growth factors other than serum have been added. [8] A chondrocyte culture produced by the methods described in [1]-[7]. [9] A method for treating a disease in a subject, comprising administering to a subject in need thereof an effective amount of the chondrocyte culture described in [8].
[10] The method of treatment described in [9], wherein the disease is osteoarthritis.
[0010] [1] A TGP-containing composition for repairing damaged cartilage tissue. [2] The composition described in [1], wherein the damaged cartilage tissue is cartilage tissue damaged by osteoarthritis. [3] The composition described in [1] or [2], wherein the repair is normalization of the degenerative state of damaged cartilage tissue. [4] The composition described in any one of [1] to [3], wherein the repair is represented by one or more indicators selected from the group consisting of chondrocyte proliferation, promotion or retention of hyaluronic acid secretion, promotion of miR140 secretion, an increase in CD44-positive cells, and proliferation of mesenchymal stem cells (MSCs). [5] The composition described in any one of [1] to [4], wherein the repair is performed in vitro or in vivo. [6] The composition described in any one of [1] to [5], comprising one or more tissues or cells selected from the group consisting of chondrocytes, chondrocyte precursor cells or MSCs, chondrocyte cultures, and cartilage tissue. [7] The composition described in any one of [1] to [6], wherein the chondrocytes or cartilage tissue are autologous cells or autologous tissue. [8] A method for producing a chondrocyte culture and a culture secretion, comprising culturing cells derived from cartilage tissue of an elderly person in a TGP-containing composition. [9] The method according to [8], wherein the cartilage tissue is cartilage tissue damaged by osteoarthritis of the knee.
[10] The method according to [8] or [9], further comprising a step of separating the chondrocyte culture from the culture secretion.
[0011]
[11] A method for growing or maintaining undifferentiated cells, comprising: The method comprises the step of culturing cells, including cells obtained from cartilage tissue, in a TGP-containing composition.
[12] The method according to
[11] , wherein the undifferentiated cells are expanded or maintained in chondrocyte culture.
[13] The method according to
[11] or
[12] , further comprising the step of adding undifferentiated cells.
[14] The method according to any one of
[11] to
[13] , wherein the undifferentiated cells are MSCs.
[15] The method according to any one of
[11] to
[14] , wherein the cartilage tissue is cartilage tissue damaged by osteoarthritis.
[0012]
[16] An undifferentiated cell produced by the method according to any one of
[11] to
[15] .
[17] A TGP-containing composition for preventing the degradation of high molecular weight components secreted from cells.
[18] A method for producing a macromolecular component secreted from a cell, the method comprising the step of culturing the cell in a TGP-containing composition.
[19] The composition or method described in
[17] or
[18] , wherein the high molecular weight component secreted from the cells is hyaluronic acid.
[20] The composition or method described in any one of
[17] to
[19] , wherein the cell is a human cell, and the human cell is one or more cells selected from the group consisting of human smooth muscle cells, human chondrocytes, human fibroblasts, human adipocytes, and human synovial cells. Effect of the Invention
[0013] The chondrocyte culture produced by the method of the present invention is rich in ECM and therefore has high engraftment ability, and not only has the function and tissue structure of healthy cartilage, but also can normalize the degenerated state of cartilage tissue characterized by inflammation, ECM degradation, etc. Furthermore, the chondrocyte culture contains many stem cells that contribute to cartilage regeneration, and therefore has the effect of repairing and maintaining cartilage tissue in a degenerated state such as osteoarthritis for a long period of time. [Brief description of the drawings]
[0014] [Figure 1] FIG. 1 shows histological images of samples obtained by plate culture (Comparative Example 1) and TGP culture (Example 1). [Diagram 2] FIG. 2 shows immunostained images of CD44 in samples obtained by plate culture (Comparative Example 1) and TGP culture (Example 1). [Diagram 3] FIG. 3 shows the change in the amount of α2-6 sialic acid present on the cell membrane of TGP-cultured samples in response to SNA. [Figure 4]FIG. 4 shows the change in the amount of α2-6 sialic acid present on the cell membrane of TGP-cultured samples in response to SSA. [Diagram 5] FIG. 5 shows the change in the amount of α2-6 sialic acid present on the cell membrane of TGP-cultured samples in response to TJA-1. [Figure 6] FIG. 6 shows the change in the amount of α1-3 fucose in response to UEA-1 present on the cell membrane of TGP-cultured samples. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] The present invention will be described in detail below. Unless otherwise defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. All patents, applications and other publications and information referenced herein are incorporated herein by reference in their entirety. In addition, in the event of any discrepancy between the publications referenced herein and the description herein, the description herein shall control.
[0016] The present invention relates to a method for producing a chondrocyte culture having high tissue regeneration capacity, which comprises culturing a cell population isolated from cartilage tissue with a thermoreversible polymer. In the present disclosure, "cartilage tissue" refers to tissue derived from cartilage. Cartilage includes, but is not limited to, articular cartilage, epiphyseal plate, costal cartilage, tracheal cartilage, laryngeal cartilage, sacroiliac joint, temporomandibular joint, sternoclavicular joint, intervertebral disc, pubic symphysis, meniscus, articular disc, external auditory canal, Eustachian tube, auricular cartilage, and epiglottis cartilage. Cartilage tissue may be derived from any organism. Human cartilage tissue is preferred because it causes less rejection when bone tissue culture is transplanted into damaged human cartilage. Either autologous or allogeneic tissue may be used, but autologous tissue is preferred because it causes less rejection when applied to a subject.
[0017] The cartilage tissue used in the present invention can form a chondrocyte culture having a tissue structure similar to that of healthy cartilage tissue, regardless of the condition of the subject from which the cartilage tissue is derived. Therefore, the cartilage tissue may be derived from a subject in any condition, for example, articular cartilage collected from a subject with osteoarthritis. The site from which such articular cartilage is collected may be a weight-bearing or non-weight-bearing site, or the cartilage tissue may be collected from a weight-bearing site damaged by osteoarthritis.
[0018] Since the chondrocyte culture produced by the present invention does not develop abnormalities such as calcification even when cultured for a long period of time, it is possible to harvest the chondrocyte culture from a subject with grade 1, culture it until it progresses to grade 3 or later, and then transplant the produced chondrocyte culture into the subject. Therefore, the OA grade of the subject to be harvested may be any of 1 to 4.
[0019] The age of the subject from which the cartilage tissue is harvested is not particularly limited. Since the chondrocyte culture produced by the present invention has high regenerative ability, the cartilage tissue may be derived from a subject aged, for example, 0 to 39 years, 40 years or older, 50 years or older, 60 years or older, 70 years or older, 80 years or older, or 90 years or older. The method for harvesting cartilage tissue may be a conventional method used in the art for harvesting biological tissue, and may be, without limitation, harvested from cartilage using a scalpel, tweezers, a biopsy punch, or the like.
[0020] In the method of the present invention, a "cell population isolated from cartilage tissue" refers to a cell population composed of the same or different types of cells obtained by isolating cartilage tissue (e.g., enzymatic treatment, mincing treatment). The cell population is not limited as long as it is a cell population contained in cartilage tissue, and includes chondrocytes, chondroprogenitor cells, mesenchymal stem cells (MSCs), pluripotent stem cells, etc.
[0021] The cartilage tissue can be isolated by a method commonly used in the art for isolation of biological tissues, such as an enzymatic method or a physical method. An enzymatic method is, but is not limited to, an incubation using one or more enzymes at a temperature at which the cells that constitute the cartilage tissue can survive (e.g., 37°C). In the enzymatic isolation method, an enzyme commonly used in the art for isolating cells from cartilage tissue can be used under the treatment conditions of temperature, concentration, and time corresponding thereto.
[0022] The enzyme is not limited as long as it can separate cartilage tissue, and examples of the enzyme that can be used include dispase I or II, collagenase I or II, metalloprotease, trypsin, hyaluronidase, pepsin, aminopeptidase, lipase, amylase, etc. From the viewpoint of being able to decompose cartilage tissue in a short time and with minimal invasiveness, preferably, any one of dispase I or II, collagenase, metalloprotease, actase, or trypsin may be used alone as the enzyme, or two or more of them may be used in combination.
[0023] When trypsin is used, it may be in the form of trypsin-EDTA at 0.05% to 2.5%, 0.1% to 1%, or 0.15% to 0.3%, and is preferably 0.2 to 0.25% in terms of enabling minimally invasive separation. The separation treatment time using trypsin-EDTA is not limited and may be 1 minute to 2 hours, 3 minutes to 1 hour, or 10 minutes to 40 minutes, and is preferably 30 minutes in terms of not damaging stem cells. When collagenase II is used, the concentration is not limited, but is preferably 0.1 to 30 mg / ml, 0.5 to 10 mg / ml, or 0.75 to 5 mg / ml, and from the viewpoint of minimally invasive separation, 0.8 to 2 mg / ml is particularly preferred. The separation treatment time is not limited as long as live cells are not killed, and may be, for example, 1 to 24 hours, 3 to 20 hours, 7 to 18 hours, or 10 to 16 hours, and from the viewpoint of minimally invasive separation of stem cells, 12 to 16 hours is preferred.
[0024] When trypsin and collagenase II are used in combination, there are no limitations and any combination of concentrations and treatment times can be used. From the viewpoint of isolating stem cells in a minimally invasive manner while maintaining the phenotype of chondrocytes, a combination of treatment with trypsin-EDTA (0.25% solution) at 37°C for 30 minutes and collagenase II solution (1 mg / ml) at 37°C for 12 to 16 hours is preferred.
[0025] Physical methods include, but are not limited to, mincing or crushing the cartilage tissue using a scalpel, ultrasonic waves, a homogenizer, a strainer, etc. The physical methods can be optionally combined with the enzymatic methods detailed above. The separated cells may be separated by any known method such as a filter, a cell strainer, etc. into cells separated by the separation treatment and tissue fragments or matrix that are not completely separated. By separating the cells, a cell population with a uniform size or function can be obtained.
[0026] In the method of the present invention, the thermoreversible polymer (also referred to as "TGP" in this specification) refers to a polymer that has the property of thermoreversibly generating a crosslinked structure or a network structure and thermoreversibly forming a hydrogel that retains a separated liquid such as water inside the structure based on the structure. Also, a hydrogel refers to a gel that contains a crosslinked or network structure made of a polymer and water supported or retained in the structure. In the present invention, the thermoreversible polymer forms an environment similar to that of cartilage tissue in a living body due to the crosslinked or network structure unique to the thermoreversible polymer, so any polymer can be used in the method of the present invention as long as it is a thermoreversible polymer.
[0027] (Sol-gel transition temperature) In the present invention, the definitions and measurements of the "sol state", "gel state", and "sol-gel transition temperature" are based on the definitions and methods described in the literature (H. Yoshioka et al., Journal of Macromolecular Science, A31(1), 113 (1994)). That is, the dynamic elastic modulus of the sample at an observation frequency of 1 Hz is measured by gradually changing the temperature from the low temperature side to the high temperature side (1°C / 1 minute), and the temperature at which the storage elastic modulus (G', elastic term) of the sample exceeds the loss elastic modulus (G", viscous term) is defined as the sol-gel transition temperature. Generally, the state where G">G' is defined as the sol state, and the state where G"<G' is defined as the gel state. When measuring this sol-gel transition temperature, the following measurement conditions can be preferably used.
[0028] <Measurement Conditions for Dynamic and Loss Elastic Moduli> Measuring instrument (product name): Stress-controlled rheometer AR500, manufactured by TA Instruments Concentration of the sample solution (or separation liquid) (however, as the concentration of the "hydrogel-forming polymer having a sol-gel transition temperature"): 10 (wt)% Amount of the sample solution: approximately 0.8 g Shape and dimensions of the measuring cell: Acrylic parallel disks (diameter 4.0 cm), gap 600 μm Measurement frequency: 1 Hz Applied stress: within the linear region
[0029] In the present invention, the above sol-gel transition temperature is preferably higher than 0°C and 37°C or lower, and more preferably higher than 5°C and 35°C or lower (particularly 10°C or higher and 33°C or lower). The TGP having such a suitable sol-gel transition temperature can be easily selected from the specific compounds described below according to the above-described screening method (sol-gel transition temperature measurement method).
[0030] The TGP of the present invention is not particularly limited as long as it exhibits the above-mentioned thermoreversible sol-gel transition (i.e., has a sol-gel transition temperature). Specific examples of polymers whose aqueous solutions have a sol-gel transition temperature and reversibly exhibit a sol state at a temperature lower than the transition temperature include polyalkylene oxide block copolymers, such as block copolymers of polypropylene oxide and polyethylene oxide; etherified celluloses, such as methyl cellulose and hydroxypropyl cellulose; and chitosan derivatives (KR Holme.et al. Macromolecules, 24, 3828 (1991)).
[0031] (Suitable hydrogel-forming polymer) A hydrogel-forming polymer that utilizes hydrophobic bonds for cross-linking and that can be suitably used as the TGP of the present invention is preferably formed by combining multiple blocks having a cloud point with a hydrophilic block, from the viewpoint of preventing separation of the TGP from the medium and maintaining a stable surrounding of the cell population. The hydrophilic block is preferably present so that the hydrogel becomes water soluble at a temperature below the sol-gel transition temperature, and the cloud point blocks are preferably present so that the hydrogel changes to a gel state at a temperature above the sol-gel transition temperature.
[0032] In other words, since a block having a cloud point dissolves in water at a temperature lower than the cloud point and becomes insoluble in water at a temperature higher than the cloud point, the block serves as a crosslinking point consisting of hydrophobic bonds for forming a gel at a temperature higher than the cloud point. In other words, the cloud point derived from the hydrophobic bonds corresponds to the sol-gel transition temperature of the hydrogel. However, the cloud point does not necessarily have to coincide with the sol-gel transition temperature, because the cloud point of the above-mentioned "block having a cloud point" is generally influenced by the bond between the block and a hydrophilic block.
[0033] The hydrogel used in the present invention utilizes the property that hydrophobic bonds not only become stronger with increasing temperature, but also that this change is reversible with respect to temperature. In order to form multiple crosslinking points within one molecule, form a gel with excellent stability, and enable stable growth of chondrocyte cultures against reversible temperature changes, it is preferable that TGP has multiple "blocks having a cloud point." On the other hand, as described above, the hydrophilic block in the TGP has the function of changing the TGP to water-soluble at a temperature lower than the sol-gel transition temperature, and has the function of forming a hydrogel state while preventing the hydrophobic binding force from increasing too much at a temperature higher than the transition temperature, which would cause the hydrogel to aggregate and precipitate.
[0034] Furthermore, from the viewpoint of using the chondrocyte culture of the present invention in cell therapy, it is preferable that the TGP used in the present invention is degraded and absorbed in vivo, i.e., it is preferable that the TGP of the present invention is degraded in vivo by hydrolysis or enzymatic reaction, and absorbed and excreted as a low molecular weight substance that is harmless to the body. When the TGP of the present invention is composed of multiple blocks having a cloud point and a hydrophilic block bonded together, it is preferable that at least one of the blocks having a cloud point and the hydrophilic block, and preferably both of them, are degraded and absorbed in the body.
[0035] (Multiple blocks with cloud points) The block having a cloud point is preferably a block of a polymer exhibiting a negative solubility-temperature coefficient in water, and more specifically, a polymer selected from the group consisting of polypropylene oxide, copolymers of propylene oxide and other alkylene oxides, poly N-substituted acrylamide derivatives, poly N-substituted methacrylamide derivatives, copolymers of N-substituted acrylamide derivatives and N-substituted methacrylamide derivatives, polyvinyl methyl ether, and partial acetylated polyvinyl alcohol. From the viewpoint of enabling stable culture of the cell population or chondrocyte culture of the present invention, poly N-substituted acrylamide derivatives are preferred.
[0036] In order to make the block having a cloud point degradable and absorbable in vivo, it is effective to make the block having a cloud point a polypeptide consisting of hydrophobic and hydrophilic amino acids. Alternatively, a polyester-type biodegradable polymer such as polylactic acid or polyglycolic acid can be used as the block having a cloud point that is degradable and absorbable in vivo.
[0037] It is preferable that the cloud point of the above polymer (block having a cloud point) is higher than 4°C and lower than 40°C in order to make the sol-gel transition temperature of the polymer used in the present invention (compound in which multiple blocks having a cloud point and a hydrophilic block are combined) higher than 0°C and lower than 37°C. The cloud point can be measured, for example, by cooling an aqueous solution of about 1% by mass of the above polymer (block having a cloud point) to form a transparent homogeneous solution, and then gradually increasing the temperature (at a rate of temperature increase of about 1°C / min) until the point at which the solution first becomes cloudy is determined as the cloud point.
[0038] Specific examples of poly-N-substituted acrylamide derivatives and poly-N-substituted methacrylamide derivatives that can be used in the present invention are listed below: poly-N-acryloylpiperidine; poly-Nn-propylmethacrylamide; poly-N-isopropylacrylamide; poly-N,N-diethylacrylamide; poly-N-isopropylmethacrylamide; poly-N-cyclopropylacrylamide; poly-N-acryloylpyrrolidine; poly-N,N-ethylmethylacrylamide; poly-N-cyclopropylmethacrylamide; poly-N-ethylacrylamide. From the viewpoint of enabling stable culture of the cell population or chondrocyte culture of the present invention, poly-N-isopropylacrylamide is preferred.
[0039] The above polymer may be a homopolymer or a copolymer of the monomer constituting the above polymer with another monomer. As the other monomer constituting such a copolymer, either a hydrophilic monomer or a hydrophobic monomer can be used. In general, when copolymerized with a hydrophilic monomer, the cloud point of the product increases, and when copolymerized with a hydrophobic monomer, the cloud point of the product decreases. Therefore, by selecting the monomer to be copolymerized, a polymer having a desired cloud point (for example, a cloud point higher than 4° C. and lower than 40° C.) can be obtained.
[0040] (hydrophilic monomer) Examples of the hydrophilic monomer include, but are not limited to, N-vinylpyrrolidone, vinylpyridine, acrylamide, methacrylamide, N-methylacrylamide, hydroxyethyl methacrylate, hydroxyethyl acrylate, hydroxymethyl methacrylate, hydroxymethyl acrylate, acrylic acid, methacrylic acid and salts thereof having an acidic group, vinyl sulfonic acid, styrene sulfonic acid, etc., as well as N,N-dimethylaminoethyl methacrylate, N,N-diethylaminoethyl methacrylate, N,N-dimethylaminopropyl acrylamide and salts thereof having a basic group.
[0041] (Hydrophobic Monomer) On the other hand, examples of the hydrophobic monomer include acrylate derivatives and methacrylate derivatives such as ethyl acrylate, methyl methacrylate, and glycidyl methacrylate, N-substituted alkyl methacrylamide derivatives such as Nn-butyl methacrylamide, vinyl chloride, acrylonitrile, styrene, and vinyl acetate, but are not limited to these.
[0042] (hydrophilic block) On the other hand, specific examples of the hydrophilic block to be bound to the block having the above-mentioned cloud point include methylcellulose, dextran, polyethylene oxide, polyvinyl alcohol, poly N-vinylpyrrolidone, polyvinylpyridine, polyacrylamide, polymethacrylamide, poly N-methylacrylamide, polyhydroxymethylacrylate, polyacrylic acid, polymethacrylic acid, polyvinylsulfonic acid, polystyrenesulfonic acid, and salts thereof; poly N,N-dimethylaminoethyl methacrylate, poly N,N-diethylaminoethyl methacrylate, poly N,N-dimethylaminopropylacrylamide, and salts thereof, etc. In one embodiment of the present invention, when poly-N-isopropylacrylamide is used as the multiple blocks having a cloud point of the thermoreversible gel, an environment similar to the in vivo environment of cartilage tissue is formed, thereby increasing the proliferation ability of the cell population, and therefore polyethylene oxide is preferred as the hydrophilic block to be bound to the acrylamide.
[0043] Furthermore, it is desirable for the hydrophilic block to be decomposed, metabolized, and excreted in the body, and hydrophilic biopolymers such as proteins, such as albumin and gelatin, and polysaccharides, such as hyaluronic acid, heparin, chitin, and chitosan, are preferably used.
[0044] The method for bonding the block having a cloud point and the hydrophilic block is not particularly limited, but can be carried out, for example, by introducing a polymerizable functional group (e.g., acryloyl group) into any of the blocks and copolymerizing a monomer that gives the other block. The bond between the block having a cloud point and the hydrophilic block can also be obtained by block copolymerization of a monomer that gives the block having a cloud point and a monomer that gives the hydrophilic block. The bond between the block having a cloud point and the hydrophilic block can also be carried out by introducing reactive functional groups (e.g., hydroxyl group, amino group, carboxyl group, isocyanate group, etc.) into both blocks in advance and bonding them by chemical reaction.
[0045] In this case, a plurality of reactive functional groups are usually introduced into the hydrophilic block. The polypropylene oxide having a cloud point and the hydrophilic block can be bonded, for example, by repeatedly sequentially polymerizing propylene oxide and a monomer (e.g., ethylene oxide) constituting the "other hydrophilic block" by anionic polymerization or cationic polymerization, to obtain a block copolymer in which the polypropylene oxide and the "hydrophilic block" (e.g., polyethylene oxide) are bonded.
[0046] Such a block copolymer can also be obtained by introducing a polymerizable group (e.g., acryloyl group) to the end of polypropylene oxide, and then copolymerizing a monomer that constitutes a hydrophilic block. Furthermore, the polymer used in the present invention can also be obtained by introducing a functional group that can react with the functional group (e.g., hydroxyl group) at the end of polypropylene oxide into the hydrophilic block and reacting them. In addition, the TGP used in the present invention can also be obtained by linking a material such as Pluronic (registered trademark) F-127 (trade name, manufactured by Asahi Denka Kogyo Co., Ltd.), in which polyethylene glycol is bonded to both ends of polypropylene glycol.
[0047] In the embodiment of the polymer of the present invention that includes the block having a cloud point, the "block having a cloud point" present in the molecule is water-soluble together with the hydrophilic block at a temperature lower than the cloud point, so that the polymer completely dissolves in water and exhibits a sol state. However, when the temperature of the aqueous solution of the polymer is heated to a temperature higher than the cloud point, the "block having a cloud point" present in the molecule becomes hydrophobic, and separate molecules associate with each other through hydrophobic interactions.
[0048] On the other hand, since the hydrophilic blocks are water-soluble even at this time (when heated to a temperature higher than the cloud point), the polymer of the present invention forms a hydrogel in water having a three-dimensional network structure in which the hydrophobic associations between the blocks having a cloud point serve as crosslinking points. When the temperature of this hydrogel is again cooled to a temperature lower than the cloud point of the "block having a cloud point" present in the molecule, the block having a cloud point becomes water-soluble, the crosslinking points due to hydrophobic associations are released, the hydrogel structure disappears, and the TGP of the present invention becomes a complete aqueous solution again.
[0049] Thus, the sol-gel transition of the polymer of the present invention in a preferred embodiment is based on the reversible change in hydrophilicity and hydrophobicity of the block having a cloud point present in the molecule at the cloud point, and is therefore completely reversible in response to temperature changes. According to the studies of the present inventors, it is believed that the delicate balance of hydrophilicity and hydrophobicity of TGP in water contributes to the stability of cells when they are stored in water at low temperatures.
[0050] (Gel solubility) As described above, the hydrogel-forming polymer of the present invention, which contains at least a polymer having a sol-gel transition temperature in an aqueous solution, is substantially water-insoluble at a temperature (d°C) higher than the sol-gel transition temperature, and is reversibly water-soluble at a temperature (e°C) lower than the sol-gel transition temperature.
[0051] The above-mentioned high temperature (d°C) is preferably a temperature higher than the sol-gel transition temperature by 1°C or more, and more preferably by 2°C or more (particularly by 5°C or more). Moreover, the above-mentioned "substantially water-insoluble" preferably means that the amount of the above-mentioned polymer that dissolves in 100 ml (liters) of water at the above-mentioned temperature (d°C) is 5.0 g or less (more preferably 0.5 g or less, and particularly 0.1 g or less).
[0052] On the other hand, the above-mentioned low temperature (e°C) is preferably a temperature lower than the sol-gel transition temperature by 1°C or more (in absolute value), and more preferably by 2°C or more (particularly by 5°C or more). Moreover, the above-mentioned "water-soluble" means that the amount of the above-mentioned polymer that dissolves in 100 ml (liters) of water at the above-mentioned temperature (e°C) is preferably 0.5 g or more (even more preferably 1.0 g or more). Furthermore, "exhibiting reversible water solubility" means that an aqueous solution of the above-mentioned TGP exhibits the above-mentioned water solubility at a temperature lower than the sol-gel transition temperature even after it has been gelled once (at a temperature higher than the sol-gel transition temperature).
[0053] The above polymer preferably exhibits a viscosity of 10 to 3,000 centipoise (more preferably 50 to 1,000 centipoise) in a 10% aqueous solution at 5° C. Such a viscosity is preferably measured, for example, under the following measurement conditions. Viscometer: Stress-controlled rheometer (model: AR500, manufactured by TA Instruments) Rotor diameter: 60mm Rotor shape: parallel plate
[0054] The aqueous solution of TGP of the present invention is gelled at a temperature higher than the sol-gel transition temperature, and the gel does not substantially dissolve even when immersed in a large amount of water. The above-mentioned properties of the hydrogel formed by the TGP can be confirmed, for example, as follows. That is, 0.15 g of TGP is dissolved in 1.35 g of distilled water at a temperature lower than the sol-gel transition temperature (for example, under ice cooling) to prepare a 10 wt% aqueous solution, and the aqueous solution is poured into a plastic petri dish with a diameter of 35 mm and heated to 37°C to form a gel with a thickness of about 1.5 mm in the petri dish, and then the weight (f grams) of the entire petri dish containing the gel is measured. Next, the entire petri dish containing the gel is left to stand in 250 ml (liter) of water at 37°C for 10 hours, and then the weight (g grams) of the entire petri dish containing the gel is measured to evaluate whether the gel has dissolved from the gel surface. In this case, in the hydrogel-forming polymer of the present invention, the weight loss rate of the gel, i.e., (fg) / f, is preferably 5.0% or less, more preferably 1.0% or less (particularly 0.1% or less).
[0055] The aqueous solution of TGP of the present invention is gelled at a temperature higher than the sol-gel transition temperature, and even if it is immersed in a large amount of water (about 0.1 to 100 times the volume of the gel) the gel does not dissolve for a long period of time. Such properties of the polymer used in the present invention are achieved, for example, by the presence of two or more (plural) blocks having a cloud point in the polymer. In contrast, the inventors have found that when a similar gel is prepared using the aforementioned Pluronic (registered trademark) F-127, which is made of polypropylene oxide with polyethylene oxide bonded to both ends, the gel completely dissolves in water when left to stand for several hours.
[0056] In order to keep the cytotoxicity in the non-gelled state as low as possible, it is preferable to use a TGP that can gel at a concentration relative to water, i.e., {(polymer) / (polymer+water) x 100(%), of 20% or less (preferably 15% or less, and particularly 10% or less). The molecular weight of the TGP used in the present invention is preferably from 30,000 to 30 million, more preferably from 100,000 to 10 million, and even more preferably from 500,000 to 5 million.
[0057] In the method of the present invention, the step of culturing a cell population in a thermoreversible polymer (TGP) may be performed by mixing a cell population isolated from cartilage tissue with a thermoreversible polymer and culturing the cell population in a known manner. Typically, a method can be used in which a cell population isolated from cartilage tissue is dispersed in a TGP solution at a low temperature lower than the sol-gel transition temperature, the TGP is gelled at a temperature higher than the sol-gel transition temperature, and then a medium such as a culture solution is added to the cell population for culturing. By adding a medium to the gelled TGP and periodically replacing only the medium, a stable supply of nutrients can be provided to the cell population in the gel.
[0058] The culture in the present invention can be carried out under conditions that are generally used in the art. For example, typical culture conditions include culture at 37°C and 5% CO2. The culture can also be carried out at normal pressure (atmospheric pressure). In the method of the present invention, abnormal chondrocyte cultures such as calcification do not occur even when the cell population is cultured for a long period of time, so the culture period is not particularly limited. For example, the culture period may be 4 days or more, 8 days or more, 16 days or more, 21 days or more, 32 days or more, 48 days or more, 64 days or more, 72 days or more, 90 days or more, 102 days or more, 114 days or more, 126 days or more, 140 days or more, 160 days or more, 180 days or more, or 250 days or more. From the viewpoint of sufficient ECM formation, 21 days or more is preferable, 32 days or more is more preferable, and 72 days or more is even more preferable.
[0059] The culture can be carried out in a vessel of any size and shape. The medium in which TGP is dissolved and the medium to be added to the gelled TGP (sometimes referred to as "liquid medium" in this specification) are not particularly limited as long as they can maintain the survival of the cells, but typically, those mainly composed of amino acids, vitamins, and electrolytes can be used. In the present invention, the medium in which TGP is dissolved and the medium to be added to the gelled TGP may be the same or different.
[0060] In one embodiment of the present invention, the medium in which TGP is dissolved and the medium to be added to the gelled TGP are based on a basal medium for cell culture. Such basal media include, but are not limited to, DMEM, MEM, F12, DME, RPMI1640, MCDB (MCDB102, 104, 107, 120, 131, 153, 199, etc.), L15, SkBM, RITC80-7, CnT-PR, etc. Many of these basal media are commercially available, and their compositions are also publicly known. The basal medium may be used as is with a standard composition (for example, as it is commercially available), or the composition may be appropriately changed depending on the cell type and cell conditions. Therefore, the basal medium used in the present invention is not limited to those with known compositions, and includes those in which one or more components are added, removed, increased, or decreased.
[0061] In addition to the above, the medium may contain one or more additives such as serum, growth factors (e.g., FGF-2, TGF-b1, etc.), steroid components, and selenium components. The serum may be xenogeneic serum or allogeneic serum. Allogeneic serum is preferable, and among allogeneic serum, autologous serum is more preferable. The medium does not contain growth factors other than those contained in autologous serum. When culturing using TGP dissolved in such a medium, the cell population is cultured in TGP to which growth factors other than autologous serum have not been added. The concentration of serum is not particularly limited, and may be 3%, 5%, 10%, or 20% in the medium added to TGP. It is preferably 10%. In one embodiment of the present invention, the medium in which TGP is dissolved and the medium added to the gelled TGP may be composed of common components.
[0062] The "chondrocyte culture" produced by the method of the present invention refers to a cell population containing chondrocytes obtained by culturing a cell population isolated from cartilage tissue. In one embodiment, the chondrocyte cultures produced by the methods of the present invention may have a cartilage-like tissue structure in which the intercellular spaces of the cell population are filled with ECM.
[0063] The chondrocyte cultures obtained by the methods of the present invention have a higher tissue regeneration capacity than chondrocyte cultures cultured by a method that does not include a step of culturing the cell population with a thermoreversible polymer (referred to herein as "control cultures"). The tissue regenerative ability refers to the tissue regenerative ability of cartilage tissue to which the cell population is applied. In one aspect, tissue regeneration ability can be quantified by applying (implanting) a chondrocyte culture to a subject's cartilage tissue, and after a predetermined period of time, observing the condition of the tissue at the application site (implantation site), for example, tissue size, tissue microstructure, the ratio of damaged tissue to normal tissue, tissue function, etc., and scoring these.
[0064] In one embodiment, the tissue regeneration ability may be the ability to express one or more genes selected from SOX9, COL2A1, miR140, and miR21. The chondrocyte culture produced by the method of the present invention has higher expression of one or more genes selected from SOX9, COL2A1, miR140, and miR21 than a control culture. Thus, the present invention may be a method for increasing the ability of a cell population isolated from cartilage tissue to express one or more genes selected from SOX9, COL2A1, miR140, and miR21.
[0065] SOX9 and COL2A1 are known to be genes that are expressed during normal cartilage tissue formation. In addition, miR140-3p or -5p, or miR21-5p derived from miR140 or miR21, are effective in normalizing the degenerative state of cartilage tissue, which is characterized by inflammation in cartilage tissue and ECM degradation that occurs in osteoarthritis (Karlsen et al., Mol Ther Nucleic Acids. 2016 Oct 11;5(10); Miyaki et al., Arthritis Rheum. 2009 Sep;60(9):2723-30; Si et al., Osteoarthritis Cartilage. 2017 Oct;25(10):1698-1707; Miyaki et al., Genes Dev. 2010 Jun 1;24(11):1173-85; Hai et al.,. J Orthop Surg Res. 2019;14:118, etc.).
[0066] Specifically, when miR140 is highly expressed in cartilage tissue, miR140-3p or 5p increases in the cartilage tissue, resulting in normalization of the degenerative state of the cartilage tissue through, but not limited to, a decrease in the expression or secretion of ECM degrading enzymes such as MMP-13 and ADAMTS-5, a decrease in the expression or secretion of inflammatory mediators such as IL1B, IL6, and IL8, and an increase in the expression of proteins involved in ECM synthesis such as SOX9, ACAN, and chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CSGALNACT1). Therefore, when the chondrocyte culture of the present invention is applied to the cartilage tissue of a subject, particularly a subject with osteoarthritis, it can not only supplement normal cartilage tissue at the application site, but also normalize the degenerative state of the cartilage tissue around the application site, thereby maintaining the therapeutic effect over a long period of time.
[0067] In addition, when miR21 is highly expressed in cartilage tissue, mi21-5p increases in the cartilage tissue, normalizing the degenerative state of the cartilage tissue through, but not limited to, a decrease in the expression or secretion of ECM degrading enzymes such as MMP-13 and ADAMTS-5, and an increase in the expression of proteins involved in ECM synthesis such as COL2A1. Therefore, the therapeutic effect can be maintained for a long period of time, just like miR140.
[0068] As used herein, high gene expression means, without limitation, that the expression level of a given gene is higher by 101% or more, 105% or more, 110% or more, 130% or more, 140% or more, 150% or more, 160% or more, 170% or more, 180% or more, 190% or more, or 200% or more, relative to the control culture.
[0069] Techniques for measuring gene expression levels are well known in the art. Techniques for measuring protein expression levels include, but are not limited to, western blotting using monoclonal or polyclonal antibodies as described above, EIA, ELISA, RIA, immunohistochemistry, immunocytochemistry, flow cytometry, mass spectrometry, etc. Techniques for measuring gene expression levels include, but are not limited to, northern blotting, southern blotting, DNA microarray analysis, RNase protection assay, PCR such as RTPCR and real-time PCR (qPCR), in situ hybridization, etc.
[0070] In this disclosure, SOX9 (also referred to as CMD1, CMPD1, SRA1, SRXX2, and SRXY10) is a gene encoding SRY-box transcription factor 9, and the gene sequence of human SOX9 is registered under accession number NM_000346, etc., and the sequence is as shown in SEQ ID NO:1. In the present disclosure, COL2A1 (also referred to as ANFH, AOM, COL11A3, SEDC, and STL1) is a gene encoding collagen type II alpha 1 chain, and the gene sequence of human COL2A1 is registered under accession number NM_001844.5, etc., and the sequence is as shown in SEQ ID NO: 2.
[0071] As used herein, the term "microRNA (miRNA)" refers to a 10-25 base RNA that is transcribed as a hairpin-like RNA precursor, cleaved by a dsRNA cleaving enzyme having RNaseIII cleavage activity, incorporated into a protein complex called RISC, and is involved in the translational inhibition of mRNA. The term "miRNA" also includes "miRNA" and precursors of "miRNA" (pre-miRNA, pri-miRNA), and also includes "miRNA" that encodes miRNAs having biological functions equivalent to those of the miRNAs encoded by these, such as homologs (i.e., homologs), mutants such as gene polymorphisms, and derivatives. Examples of "miRNA" that encode such precursors, homologs, mutants, or derivatives include "miRNA" that can be identified by miRBase (http: / / www.mirbase.org / ) and have a base sequence that hybridizes with a complementary sequence of a specific base sequence under stringent conditions.
[0072] In the present disclosure, human mir-140 is registered as miRbase ID: stem-loop sequence hsa-mir-140, miRbase accession number.MI0000456, and is as shown in SEQ ID NO:3. In the present disclosure, human miR140-3p is registered as miRbase ID: Mature sequence hsa-miR-140-3p, miRbase accession number.MIMAT0004597, and is as shown in the RNA sequence "uaccacaggguagaaccacgg" shown in SEQ ID NO:4. In the present disclosure, human miR140-5p is registered as miRbase ID: Mature sequence hsa-miR-140-5p, miRbase accession number.MIMAT0000431, and has the RNA sequence "cagugguuuuacccuaugguag" as shown in SEQ ID NO:5.
[0073] In the present disclosure, human mir-21 is registered as miRbase ID: stem-loop sequence hsa-mir-21, miRbase accession number.MI0000077, and is as shown in sequence number 6. In the present disclosure, human miR21-3p is registered as miRbase ID: Mature sequence hsa-miR-21-3p, miRbase accession number.MIMAT0004494, and is as shown in the RNA sequence "caacaccagucgaugggcugu" shown in SEQ ID NO:7. In the present disclosure, human miR21-5p is registered as miRbase ID: Mature sequence hsa-miR-21-5p, miRbase accession number.MIMAT0000076, and is as shown in the RNA sequence "uagcuuaucagacugauguuga" shown in SEQ ID NO:8.
[0074] In one aspect, the tissue regeneration ability is the ability of the chondrocyte culture to retain miRNA. The retention ability is the ability of the chondrocyte culture to retain miRNA in the chondrocyte culture. The ability to retain miRNA in the chondrocyte culture may be the ability to retain miRNA in the chondrocyte culture without secreting it during culture. By retaining miRNA in the chondrocyte culture during culture, when the chondrocyte culture is applied to a target, a chondrocyte culture that can secrete miRNA at a high concentration to the application site and the surrounding area of the application site can be obtained.
[0075] Examples of miRNAs include, but are not limited to, miR140, miR21, miR-125b, Has-miR-15a, miR-30a, miR-199a, miR-210, miR-221-3p, miR-92a-3p, miR-142-3p, miR-27a, miR-27b, miR26a-5p, miR-26a, miR-26b, miR-373, miR-127-5p, miR-320, miR-9, miR-634, miR-221-3p, miR-370miR-145, miR-130A, miR-145, and miR-562-5p, which can normalize the degenerative state of cartilage tissue (Zhang et al. J Arthritis. 2017 Apr;6(2). pii: 239. doi: 10.4172 / 2167-7921.1000239), preferably miR140 (including miR140-3p and -5p), miR21 (including miR21-3p and -5p), particularly preferably miR140 (including miR140-3p and -5p).
[0076] A high miRNA retention capacity refers to the presence of miRNA in the chondrocyte culture during culture at a concentration that is, without limitation, 101% or more, 105% or more, 110% or more, 130% or more, 140% or more, 150% or more, 160% or more, 170% or more, 180% or more, 190% or more, or 200% or more higher than the control culture during culture. In one embodiment, a high miRNA retention capacity refers to the presence of miRNA in the liquid medium of the chondrocyte culture during culture at a concentration that is, without limitation, 99% or less, 95% or less, 97% or less, 95% or less, 90% or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, or 10% or less lower than the medium (liquid medium) of the control culture during culture. In one aspect, high miRNA retention refers to the presence of a high concentration of miRNA in the chondrocyte culture during culture relative to a control culture during culture, and the presence of a low concentration of miRNA in the medium of the chondrocyte culture during culture relative to the liquid medium of the control culture.
[0077] In one embodiment, the tissue regeneration ability may be the stem cell content in the chondrocyte culture. The chondrocyte culture produced by the method of the present invention has a higher stem cell content than the control culture. Thus, the present invention may be a method for maintaining or expanding stem cells in a cell population isolated from cartilage tissue. In one embodiment, the stem cell content is not limited, but may be the amount or ratio of stem cells in the cell culture. The stem cells are not limited to somatic stem cells such as chondrocyte precursor cells and mesenchymal stem cells, or pluripotent stem cells such as ES cells, iPS cells, and ntES cells, as long as they have the ability to differentiate into chondrocytes.
[0078] The content of stem cells can be measured by a method for measuring stem cells known in the art, including, but not limited to, measuring the amount of α1-2 fucose reacting with lectins such as UEA-1 present in the cell membrane of cells contained in the chondrocyte culture, or α2-6 sialic acid reacting with lectins such as SNA, SSA, TJA-I, or other cell surface markers or gene expression correlated with changes in the amount of α1-2 fucosic acid or α2-6 sialic acid. A high level of α1-2 fucose present in the cell membrane of cells contained in the chondrocyte culture indicates the presence of a large number of pluripotent stem cells, and a high level of α2-6 sialic acid indicates the presence of a large number of somatic stem cells with high differentiation potential. (See Wang et al, Cell Res. 2011 Nov;21(11):1551-63; Tateno et al, Glycobiology. 2016 Dec;26(12):1328-1337, WO2016006712A1).
[0079] "Differentiation potential" refers to the ability of a cell to change into other types of cells, such as precursor cells or somatic cells, when placed in an appropriate differentiation-inducing condition. In general, when somatic stem cells are cultured for a long period of time, their proliferation ability and differentiation potential tend to decrease. Somatic stem cells with reduced differentiation potential cannot change into other types of cells, such as precursor cells or somatic cells, even though they have somatic stem cell markers on their cell surface, and therefore do not have the ability to regenerate tissue.
[0080] The chondrocyte culture produced by the method of the present invention has a high content of somatic stem cells with high differentiation potential. The content of somatic stem cells with high differentiation potential may be, without limitation, the amount or ratio of somatic stem cells with high differentiation potential in the cell culture per unit amount. In one aspect, the present invention may be a method for maintaining or increasing the differentiation potential of somatic stem cells in a cell population isolated from cartilage tissue. In another aspect, the present invention may be a method for maintaining or proliferating somatic stem cells with high differentiation potential in a cell population isolated from cartilage tissue. The somatic stem cells are not limited as long as they are somatic stem cells that can differentiate into chondrocytes, and may be chondrocyte precursor cells, mesenchymal stem cells, etc.
[0081] When a chondrocyte culture containing a large amount of such stem cells or somatic stem cells with high differentiation potential is applied to the target cartilage tissue, chondrocytes differentiated from the cells with high differentiation potential can be constantly supplied to the application site, so that normal cartilage tissue can be repaired and maintained for a long period of time. Furthermore, if the stem cells or somatic stem cells with high differentiation potential are mesenchymal stem cells, they have high abilities to normalize damaged cartilage tissue and recover from damage, such as protecting chondrocytes from apoptosis, anti-inflammation and anti-fibrosis of cartilage tissue, and can maintain the therapeutic effect for a long period of time.
[0082] The amount of α1-2 fucose reacting with a lectin such as UEA-1, or α2-6 sialic acid reacting with a lectin such as SNA, SSA, TJA-I, present in the cell membrane of cells contained in a chondrocyte culture can be measured using, without limitation, flow cytometry, Western blot, immunostaining, antibody overlay lectin microarray, etc., using the lectin or an antibody that specifically reacts with α1-2 fucose or α2-6 sialic acid to which the lectin reacts. As a method for measuring other cell surface markers or gene expression, etc. that correlate with the change in the amount of the α1-2 fucosic acid or α2-6 sialic acid, a conventional method for measuring cell surface markers or gene expression in the art can be used.
[0083] The chondrocyte culture produced by the method of the present invention contains more stem cells or somatic stem cells with high differentiation potential than a control culture. The term "containing more stem cells or somatic stem cells with high differentiation potential" means, without limitation, that the content of cells having α1-2 fucosic acid or α2-6 sialic acid, or the expression of cell surface markers or genes correlating therewith, is higher by 101% or more, 105% or more, 110% or more, 130% or more, 140% or more, 150% or more, 160% or more, 170% or more, 180% or more, 190% or more, or 200% or more than the control culture.
[0084] In one embodiment, the tissue regeneration ability may be the ability of a chondrocyte culture to secrete hyaluronic acid. The chondrocyte culture produced by the method of the present invention has a higher ability to secrete hyaluronic acid than a control culture. Therefore, the present invention may be a method for enhancing the secretion ability in a cell population isolated from cartilage tissue. It is known that hyaluronic acid acts suppressively on the expression of ECM decomposition enzymes, alleviates matrix and anti-inflammatory factors that have migrated from cartilage, and controls the expression of inflammation-related factors (Ohtsuki.et al.J Orthop Res. 2018 Aug 17. doi: 10.1002 / jor.24126).
[0085] Therefore, when the chondrocyte culture produced by the method of the present invention is applied to a subject's cartilage tissue, it not only complements normal cartilage tissue at the application site, but also suppresses ECM degradation or inflammation around the application site, thereby normalizing the degenerative state of the cartilage tissue around the application site and enabling the repair and maintenance of normal cartilage tissue over the long term.
[0086] The method for measuring the secretion ability of hyaluronic acid can be to quantify the amount of hyaluronic acid in medium (liquid medium) or TGP over time. Hyaluronic acid can be quantified by mass spectrometry, liquid chromatography, MALDI-TOF, etc., or by a commercially available kit, without being limited thereto. A high hyaluronic acid secretion ability means, without limitation, a hyaluronic acid secretion ability that is 101% or more, 105% or more, 110% or more, 130% or more, 140% or more, 150% or more, 160% or more, 170% or more, 180% or more, 190% or more, or 200% or more higher than the control culture.
[0087] Furthermore, the chondrocyte culture produced by the method of the present invention is rich in ECM and therefore easily grows at the site of injury. Therefore, the chondrocyte culture produced by the method of the present invention can be used for transplantation. In addition, the chondrocyte culture has high expression levels of miR140 and miR21, contains many stem cells, and has a high secretion amount of hyaluronic acid, so it is preferably used for the treatment of osteoarthritis of grade 2 or higher or in the elderly.
[0088] The present invention further includes a chondrocyte culture produced by the method of the present invention. The chondrocyte culture of the present invention is as described above. The present invention includes a method for treating a disease in a subject, comprising administering to a subject in need thereof an effective amount of the chondrocyte culture of the present invention. The disease is not limited to a cartilage-related disease, and includes osteoarthritis, rheumatoid arthritis, osteosarcoma, femoral head necrosis, acetabular dysplasia, meniscus injury, traumatic arthritis, physical cartilage loss or damage due to sports, accidents, etc. The method of application (administration) to a subject may be transplantation of the chondrocyte culture. The transplantation of the chondrocyte culture may be, but is not limited to, delivered to the affected area by injection into cartilage tissue, or by arthroscopic surgery and incision, and may be fixed to the affected area using any tissue adhesive such as fibrin gel, or by anastomosis. In the treatment method of the present invention, various additional components can be contained and applied, such as a pharma- ceutically acceptable carrier, a component that enhances engraftment, etc., a further active ingredient, etc. Any known additional component can be used as such an additional component, and those skilled in the art will be familiar with these additional components. The present invention will be described in more detail below by giving specific embodiments of the present invention, but the present invention is not limited to these specific examples. EXAMPLES
[0089] [Production Example 1] 42.0g of N-isopropylacrylamide and 4.0g of n-butyl methacrylate were dissolved in 592g of ethanol. An aqueous solution of 11.5g of polyethylene glycol dimethacrylate (PDE6000, manufactured by Nippon Oil & Fats Co., Ltd.) dissolved in 65.1g of water was added to the solution and heated to 70°C under a nitrogen stream. While maintaining the temperature at 70°C under a nitrogen stream, 0.4mL of N,N,N',N'-tetramethylethylenediamine (TEMED) and 4mL of 10% ammonium persulfate (APS) aqueous solution were added and reacted with stirring for 30 minutes. Further, 0.4mL of TEMED and 4mL of 10% APS aqueous solution were added four times at 30-minute intervals to complete the polymerization reaction. After cooling the reaction solution to below 5°C, it was diluted with 5L of cooled distilled water at 5°C and concentrated to 2L at 5°C using an ultrafiltration membrane with a molecular weight cutoff of 100,000.
[0090] The concentrated solution was diluted by adding 4 L of cooled distilled water, and the above ultrafiltration concentration operation was carried out again. The above dilution and ultrafiltration concentration operations were repeated five more times to remove those with a molecular weight of 100,000 or less. The material that was not filtered by this ultrafiltration (those that remained in the ultrafiltration membrane) was collected and freeze-dried to obtain 40 g of the TGP of the present invention having a molecular weight of 100,000 or more. 1 g of the TGP of the present invention obtained above was dissolved in 9 g of distilled water under ice cooling to obtain a 10 wt% aqueous solution. The storage modulus of this aqueous solution was measured using a stress-controlled rheometer (AR500, manufactured by TA Instruments) at an applied frequency of 1 Hz, and was 43 Pa at 10°C, 680 Pa at 25°C, and 1310 Pa at 37°C. This temperature-dependent change in storage modulus was observed repeatedly and reversibly.
[0091] 1. Cultivation of cell populations isolated from cartilage tissue <Sample Collection> Cartilage tissue (approximately 10 x 5 mm, 3 mm thick) was collected from the damaged area of the knee joints of six patients with osteoarthritis grade III or IV, which had been removed by total joint replacement surgery, and immersed in PBS containing antibiotics (gentamicin (50 μg / ml), amphotericin (0.25 μg / ml), penicillin (100 Units / ml) / streptomycin (100 μg / ml)) for 30 minutes. The age and sex of each patient are listed below. [Table 1]
[0092] <Isolation of cartilage tissue> Cut each tissue piece into 1mm pieces using a scalpel. 2 The slices were then treated with Tripsin-EDTA solution (0.25%) at 37°C for 30 minutes, and then treated with collagenase II solution (1 mg / ml) at 37°C for 12 to 16 hours. After washing with DMEM solution, the slices were filtered through a filter (100 μm) and centrifuged (1800 rpm, 10 minutes). The cell population thus obtained was counted using a cell counting plate. The cell count was 1 x 10 4 ~4×10 4cells / ml.
[0093] [Comparative Example 1] Cells derived from the cartilage tissue of each sample were dispensed into a medium containing antibiotics (gentamicin (50 μg / ml), amphotericin (0.25 μg / ml), penicillin (100 Units / ml) / streptomycin (100 μg / ml)) in 10% autologous serum-containing DMEM solution and cultured in a 37°C, 5% carbon dioxide incubator. The culture solution was changed every week and cultured for 4 to 7 weeks.
[0094] [Example 1] [Culture in TGP Gel] 1 g of TGP prepared in Production Example 1 was dissolved in 9 mL of DMEM at 4°C to prepare a 10% TGP solution. Next, cells derived from cartilage tissue were dispersed and dispensed into a 6-well plate. After leaving it at room temperature to form a gel, 7 - 8 ml of a medium containing antibiotics (gentamicin (50 μg / ml), amphotericin (0.25 μg / ml), penicillin (100 Units / ml) / streptomycin (100 μg / ml)) and L-Ascorbic acid (5 mg / ml) in 10% autologous serum-containing DMEM solution was added and cultured in a 5% carbon dioxide incubator (ESPEC BNA-111). The culture solution was changed every week and cultured for 20 weeks.
[0095] [Observation of Cultured Cartilage Tissue] (1) Phase-contrast microscopy observation In Comparative Example 1, spherical normal chondrocytes were confirmed at the beginning of the culture, but gradually, elongated fibroblast-like cells began to appear as the culture progressed, and from around the 12th day to around the 20th day, they gradually started to degenerate or die, and completely degenerated or died about 4 weeks after the start of the culture. For example, sample 1059 died on the 28th day, 1066 on the 23rd day, and 1068 on the 18th day.
[0096] In Example 1, chondrocyte cultures with sizes of 200 to 300 μm were observed 3 to 5 days after the start of culture, and after 21 days, they had grown to a size of 0.5 to 1.0 mm in diameter, and growth was maintained for the 20-week culture period in all samples. In Example 1, no proliferation of fibroblast-like cells was observed.
[0097] (2)HE staining A part of the sample (1059) of Comparative Example 1 was taken on the 25th day from the start of the culture, and a part of the sample (1059) of the TGP gel culture of Example 1 was taken on the 49th day from the start of the culture, and fixed with formalin and solidified with paraffin to prepare a tissue block, which was then cut to 10 μm to prepare a tissue section. The images of these observed with an optical microscope (×200) are shown in FIG. No ECM was observed in the sample of Comparative Example 1. On the other hand, in the sample of Example 1, it was found that chondrocytes were surrounded by ECM, as in general healthy cartilage tissue, and the sample had a tissue structure similar to that of healthy hyaline cartilage tissue.
[0098] (3)CD44 immunostaining Tissue sections obtained from healthy cartilage tissue, the sample of Comparative Example 1, and the sample of Example 1 were fixed with formalin, solidified with paraffin to prepare tissue blocks, and then cut at 5 μm to prepare tissue sections. After deparaffinization, the primary antibody rabbit monoclonal anti-CD44 antibody SP37 (Ventana Medical Systems Inc. USA) was reacted at room temperature for 32 minutes. Then, color development was performed using an iView DAB detection kit (Ventana Medical Systems Inc. USA). The results are shown in FIG. 2. In the chondrocyte culture, CD44-positive chondrocytes and ECM were scattered. In the plate culture sample of Comparative Example 1, ECM was not present, and only CD44-positive cells were present.
[0099] (4) Measurement of gene expression in each sample Portions of samples 1059, 1066 and 1068 of Comparative Example 1 were collected on the 14th, 17th and 26th days after the start of culture. Portions of samples 1059, 1066 and 1068 of Example 1 were collected on the 42nd day after the start of culture. Note that the collection dates differ between the samples of Comparative Example 1 and Example 1, but this is because the chondrocytes had completely died by the 42nd day in all samples of Comparative Example 1, and the samples that were collected at the latest timing during the period in which the chondrocytes were still alive were used.
[0100] The collected samples were stored at -20°C in RNAlater (registered trademark) Stabilization Solution (Invitrogen, Cat No. AM7020). Small RNA (RNA of 200 bases or less) was purified from a portion of these samples using NucleoSpin (registered trademark) miRNA Kit (TaKaRa, U0971), and qPCR of U6, miR-21-3p, miR-21-5p, miR-140-3p and miR-140-5p was performed using primers of SEQ ID NOs: 9 to 12, mRQ 3' Primer, U6 Forward Primer and U6 Reverse Primer (Mir-X (trademark) miRNA qRT-PCR TB Green Kit (TaKaRa, Z8314N) with Thermal Cycler Dice (registered trademark) Real Time System Lite (TP700, TaKaRa). The quantitative value of each miRNA was normalized by setting the expression level of U6 as 1.
[0101] Similarly, total RNA was purified using miRNAeasy Mini Kit (QIAGEN, 217004). cDNA was synthesized by reverse transcription using Superscript III reverse transcriptase (Invitrogen, 18080044), and qPCR of GAPDH, SOX9 and COL2A1 was performed using the Thermal Cycler Dice (registered trademark) Real Time System Lite with primers of SEQ ID NOs: 13 to 16 and TB Green Premix Ex Taq II (Takara, Cat No. RR820S / A / B). The quantitative value of each gene was normalized by setting the expression level of GAPDH as 1. The primers used are shown in Table 2, and the results are shown in Tables 3 to 5.
[0102] [Table 2]
[0103] [Table 3]
[0104] [Table 4]
[0105] [Table 5]
[0106] In all of the samples 1059, 1066 and 1068, it was found that the expression levels of miR-21 and miR-140 increased in Example 1 cultured in TGP gel compared to the sample of Comparison Example 1, and that miR21-5p, miR-140-3p and miR-140-5p were significantly increased. In addition, in both samples 1059 and 1068 in which the expression level of SOX9 was measured, it was found that the expression level of SOX9 was significantly increased in the sample of Example 1 compared to the sample of Comparative Example 1. In addition, in 1068 in which COL2A1 was measured, it was found that the expression level was increased in Example 1 compared to the sample of Comparative Example 1. Since it is known that the expression of miR21, miR-140, SOX9 and COL2A1 is increased during the formation of healthy cartilage tissue, it was found that the chondrocyte culture produced in Example 1 is a cartilage tissue having healthy functions. In particular, miR-140 and miR21 are known to improve the microenvironment of osteoarthritis, so the chondrocyte culture produced in Example 1 can not only promote the regeneration of cartilage tissue in the transplanted area, but also improve the degenerative condition around the transplanted area.
[0107] (5) Quantification of miR140 in liquid medium 2.0 ml of liquid medium from samples 1067 and 1068 cultured in Comparative Example 1 and Example 1 was collected on the 7th or 8th day after the start of culture and stored at -20°C in RNAlater™ Stabilization Solution (Invitrogen, Cat No. AM7020). Small RNA (RNA of 200 bases or less) was purified from a portion of these samples using NucleoSpin™ miRNA Kit (TaKaRa, U0971), and qPCR of miR-140-3p was performed using the primer of SEQ ID NO: 3 and mRQ 3' Primer (Mir-X™ miRNA qRT-PCR TB Green™ Kit (TaKaRa, Z8314N)) with Thermal Cycler Dice™ Real Time System Lite (TP700, TaKaRa). The results are shown in Table 6. The average Ct value is the number of cycles required to reach a predetermined threshold, and the lower the average Ct value, the more miR-140-3p is present in the liquid medium. In the table, "SNP" means that the sample was collected, centrifuged, filtered, and then stored, and "SNF" means that the sample was stored without such treatment.
[0108] [Table 6]
[0109] From Table 6, it was found that in all samples, miR-140-3p was present in a larger amount in the liquid medium of Comparative Example 1 compared to Example 1. In light of the fact that miR-140-3p was expressed at a higher level in the chondrocyte culture of Example 1 compared to Comparative Example 1 in the gene expression of (4), it was found that most of the miR-140-3p expressed in the chondrocyte culture of Example 1 was not secreted into the liquid medium but was retained in the chondrocyte culture. Therefore, it was revealed that tissue culture with a high miRNA content can be obtained by culturing tissue in TGP gel.
[0110] (6) Measurement of hyaluronic acid In the TGP gel culture of Example 1, 2.0 ml of liquid medium was collected on the 0th, 32nd and 113th days after the start of culture, and each was frozen at -20°C. The hyaluronic acid present in each sample was measured using a hyaluronic acid measurement kit (PG Research HA-Kit. Lot. 18H484). The results are shown in Table 7. Hyaluronic acid, which was not present at the beginning of the culture, was present at 822.8ng / ml on the 32nd day and 670.1ng / ml after 113 days. This indicates that hyaluronic acid is being secreted stably from the chondrocyte culture. Therefore, it was confirmed that the chondrocyte cultured in TGP gel is a cartilage tissue in a healthy state. [Table 7]
[0111] (7) Analysis of glycans on the cell surface of cells constituting cultured chondrocytes The chondrocyte cultures cultured in Example 1 were harvested between 14 and 126 days after the start of culture, and each TGP gel was cooled to 4°C to be recovered as an aqueous solution. The samples were dispersed in Tripsin-EDTA (0.25%) solution, and the cells were recovered. Next, the samples were centrifuged and washed three times at 4°C with DMEM (1800 rpm, 15 minutes), and each sample was frozen and stored. The samples were analyzed by the Glycan Profiling Analysis Service of GlycoTechnica Ltd. Specifically, cell membrane proteins were extracted from the thawed samples, and the membrane protein concentrations were measured by the BCA method (TaKaRa BCA Protein Assay Kit). Based on the measured protein concentrations, PBSTx was added to dilute the samples so that the protein concentration became 10 μg / mL. 100 μL of sample (10 μg / mL concentration) was added to a tube containing 100 μg of Cy3 Mono-reactive Dye Pack (GE healthcare, catalog number: PA23011), mixed with a pipette, and spun down. The tube was placed in a light-shielding bag and incubated at room temperature (25°C) for 1 hour. Desalt Spin Columns™ 0.5 ml (25 columns) (Thermo, Cat. No.: 89882) spin column was then placed into a 2 mL tube and centrifuged at 1500×g, 4° C. for 1 min to remove free Cy3. 300 μL of TBS was added to the column and centrifuged at 1500×g, 4° C. for 1 min, and this process was repeated three times. The column was placed into a new 1.5 mL tube and the labeled sample (100 μL) was added to the column and centrifuged at 1500×g, 4° C. for 2 min.
[0112] The samples were collected and 405 μL of Probing Solution (Glyco Technica) was added to obtain a sample volume of 500 μL at a concentration of 2 μg / mL. All samples were diluted using Probing Solution to concentrations ranging from 2 μg / mL to 15.625 ng / mL. After that, the LecChip Ver.1.0 (trademark, Glyco technica) was washed three times with Probing Solution, and the samples were added to the LecChip at 60 μL / well. The samples on the LecChip were reacted at 20°C for approximately 13 hours. The LecChip was incubated with GlycoLite2200 (trademark, Glyco technica) for 12 hours. TM The fluorescence pattern was measured four times in total, with exposure times of 1996, 2995, 3993, 4992, 6988, and 9984 (milliseconds) and a fixed camera gain. The obtained signals of 45 lectins were measured using GlycoStaion (registered trademark) ToolsPro Suite 1.5 (GlycoStaion (trademark) ToolsPro Suite 1.5.), and the values divided by the average intensity of 45 lectins were multiplied by 100 for average normalization based on A. Kuno et al., J. of Proteomics & Bioinformatics, Vol.1, May 2008, p.68. The results of the signal intensity for SNA, SSA, TJA-I, and UEA-1 on the cell surface of cells constituting the chondrocyte culture obtained by the above method are shown in Table 8 and Figures 3 to 6. The numbers 14 to 126 in the top row of the table indicate the number of days the collected samples were cultured.
[0113] [Table 8]
[0114] From Table 8 and Figures 3 to 6, it can be seen that in Example 1, the signals of α2-6 sialic acid-binding lectins such as SNA, SSA, and TJA-I, and α1-2 fucose-binding lectins such as UEA-1, are enhanced depending on the number of days of culture. α2-6 sialic acid that reacts with SNA, SSA, and TJA-I is a marker of somatic stem cells such as mesenchymal stem cells (MSCs) or chondrocyte precursor cells with high differentiation potential (WO2016 / 006712A1), and α1-2 fucose-binding lectins such as UEA-1 are known to be markers of pluripotent stem cells (Wang et al., Cell Res. 2011 Nov;21(11):1551-63. doi: 10.1038 / cr.2011.148. Epub 2011 Sep 6.). In the chondrocyte culture prepared in Example 1, an increase in α2-6 sialic acid and α1-2 fucose reacting with SNA, SSA, TJA-I and UEA-1 was confirmed with the passage of culture days, indicating that the tissue culture contains many somatic stem cells and pluripotent stem cells with high differentiation potential. Therefore, it was revealed that the chondrocyte culture of Example 1 is a tissue culture with high tissue regeneration ability.
[0115] 2. Hyaluronic acid retention test of TGP gel [Example 2] 5 mg of hyaluronic acid (Teijin Pharma Co., Ltd.) was dissolved in 2.5 ml of a solution containing antibiotics (gentamicin (50 μg / ml), amphotericin (0.25 μg / ml), penicillin (100 Units / ml) / streptomycin (100 μg / ml) and L-ascorbic acid (5 mg / ml)) in DMEM, and these were designated as liquid compositions 1 and 2. 1g of TGP prepared in Production Example 1 was dissolved in 9ml of DMEM at ℃ to prepare a 10% TGP solution, to which hyaluronic acid was added to achieve the same hyaluronic acid concentration as in liquid compositions 1 and 2, and the mixture was shaken to make the hyaluronic acid in the TGP solution uniform. The TGP solution was gelled at 37℃, and then 1.0ml of liquid medium (DMEM) was added, which was used as TGP composition 1 and TGP composition 2.
[0116] The hyaluronic acid-containing liquid composition and TGP composition were placed in a 37℃, 5% carbon dioxide incubator, and the hyaluronic acid concentration in each liquid medium was measured using the same method as in the above-mentioned <Measurement of hyaluronic acid>. The results are shown in Table 9. [Table 9]
[0117] In the liquid compositions 1 and 2, hyaluronic acid was present at about 13,000 ng / ml on the 7th day, but decreased to 5.6 ng / ml on the 21st day. In contrast, in the TGP compositions 1 and 2, the concentrations were 6.1 and 11.4 ng / ml on the 7th day, which is about 1 / 1000 lower than that of the liquid compositions 1 and 2, and it is recognized that most of the hyaluronic acid was retained inside the TGP gel. Furthermore, the concentrations were 10.3 and 11.5 ng / ml even at the 21st day, and the concentrations hardly changed, making it clear that the TGP gel has the ability to retain hyaluronic acid stably for a long period of time without being decomposed.
Claims
1. A method for producing a chondrocyte culture in which expression ability of one or more genes selected from SOX9, COL2A1, miR140, and miR21-5p is enhanced, comprising: Cultivating a cell population isolated from cartilage tissue in a medium containing a thermoreversible polymer; The thermoreversible polymer is formed by combining a plurality of blocks having a cloud point and a hydrophilic block, the block having a cloud point is selected from the group consisting of polypropylene oxide, a copolymer of propylene oxide and another alkylene oxide, a poly N-substituted acrylamide derivative, a poly N-substituted methacrylamide derivative, a copolymer of an N-substituted acrylamide derivative and an N-substituted methacrylamide derivative, polyvinyl methyl ether, and a partial acetylated polyvinyl alcohol; the hydrophilic block is selected from the group consisting of methyl cellulose, dextran, polyethylene oxide, polyvinyl alcohol, poly N-vinylpyrrolidone, polyvinylpyridine, polyacrylamide, polymethacrylamide, poly N-methylacrylamide, polyhydroxymethyl acrylate, polyacrylic acid, polymethacrylic acid, polyvinyl sulfonic acid, polystyrene sulfonic acid and salts thereof, poly N,N-dimethylaminoethyl methacrylate, poly N,N-diethylaminoethyl methacrylate, poly N,N-dimethylaminopropylacrylamide and salts thereof; The molecular weight of the thermoreversible polymer is 30,000 or more and 30,000,000 or less, The concentration of the thermoreversible polymer in the medium is 10% to 20%; The produced chondrocyte culture has an increased ability to express one or more genes selected from SOX9, COL2A1, miR140, and miR21-5p, as compared to a chondrocyte culture cultured by a method not including a step of culturing in a medium containing the thermoreversible polymer. The method.
2. The produced chondrocyte culture has miRNAs retained in it, as compared to a chondrocyte culture cultured by a method not including a step of culturing in a medium containing a thermoreversible polymer. The produced chondrocyte culture maintains or expands the stem cell content in the chondrocyte culture compared to a chondrocyte culture cultured by a method that does not include a step of culturing in a medium containing a thermoreversible polymer, and / or The produced chondrocyte culture has an increased ability to secrete hyaluronic acid in comparison with a chondrocyte culture cultured by a method not including a step of culturing in a medium containing a thermoreversible polymer. The method of claim 1.
3. The method of claim 2, wherein the miRNA is miR140.
4. Stem cells, (i) a pluripotent stem cell, or (ii) Chondrocyte precursor cells or mesenchymal stem cells that have the ability to change into different types of cells when placed under differentiation-inducing conditions. The method according to claim 2 or 3,
5. The method according to any one of claims 2 to 4, wherein the stem cell content is quantified by measuring the content of 1-2 fucose or α2-6 sialic acid in the chondrocyte culture.
6. The method according to claims 1 to 5, wherein the cartilage tissue is derived from a subject aged 50 or over with osteoarthritic disease.
7. The method according to any one of claims 1 to 6, wherein the medium containing the thermoreversible polymer does not contain any growth factors other than serum.
8. A chondrocyte culture having enhanced expression of one or more genes selected from SOX9, COL2A1, miR140 and miR21-5p, produced by the method according to any one of claims 1 to 7.
9. A pharmaceutical composition comprising the chondrocyte culture of claim 8.
10. 10. The pharmaceutical composition according to claim 9 for use in the treatment of osteoarthritis.
Citation Information
Patent Citations
Cell support substrate and preparation method thereof
JP2009508596A
